Pregnancy Care sFlt-1/PlGF Ratio Enhances Pre-eclampsia Diagnosis with High Sensitivity Accurate PE Risk Identification ● Early detection of pre-eclampsia based on sFlt-1/PlGF ratio or PlGF levels ● Clinically validated with high accuracy Evidence-Based Decision Making ● Uses authoritative cut-off values for early/late-onset PE assessment and short-term prediction Personalized Interpretation ● Gestational age and twin-specific reference ranges for enhanced diagnostic prec

What is Pre-eclampsia? Pre-eclampsia (PE) is a multisystem disorder characterized by new-onset hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg) occurring after 20 weeks of gestation in a previously normotensive woman, combined with evidence of maternal organ dysfunction (e.g., proteinuria, acute kidney injury, liver involvement, neurological complications, hematological abnormalities) and/or uteroplacental dysfunction. A key diagnostic criterion per recent guidelines (ISSHP 2021) is angiogenic imbalance, specifically an elevated soluble fms-like tyrosine kinase-1 (sFlt-1) to...

Screening method Management plan for preeclampsia throughout the entire gestational period Week Characteristics of the pregnant woman, medical and obstetric history PlGF measurement UTPI measurement Risk assessment A comprehensive risk assessment of maternal risk factors, MAP, PIGF and UTPI should be conducted from 11 to 13+6 weeks of pregnancy Low-risk screening High-risk screening Routine prenatal care sFlt-1/PlGF Timing recommendation for childbirth Can not be diagnosed as PE, but it is very likely to occur within 4 weeks. A retest can be conducted in 1-2 weeks based on clinical conditions...

Applicable System Poclight Nanjing Poclight Biotechnology Co., Ltd. Address: South Side, 2nd Floor, Building A02, Biopharmaceutical Valley Accelerator (Phase MI), No. 142 Huakang Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210000, P R. China E-mail: [email protected] Website: www.poclight.com